Company Reports

Recent Updates

All Reports

Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of a more than 11% compound annual growth rate in operating profits for the midterm plan ending March 2027.
Stock Analyst Note

In the first quarter of fiscal 2026, ending March 2027, Meiji's domestic food revenue grew 4% year over year, while pharmaceutical margin improved to 15.2% from 9.8%, on 13.6% growth. Management maintained guidance and announced plans to restructure its China portfolio.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of a more than 11% compound annual growth rate in operating profits for the midterm plan ending March 2027.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of a more than 11% compound annual growth rate in operating profits for the midterm plan ending March 2027.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of a more than 11% compound annual growth rate in operating profits for the midterm plan ending March 2027.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid Japanese yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of more than 11% CAGR in operating profits for the mid-term plan ending March 2027.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid Japanese yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of more than 11% CAGR in operating profits for the mid-term plan ending March 2027.
Stock Analyst Note

Meiji Holding’s numbers for fiscal 2024 (ending March 2025) were slightly below our expectations, with March-quarter sales and operating income coming in 1.7% and 6.6% below the company's guidance, respectively. This was mainly due to the drag from the nutrition business, which posted an operating margin of 4.2% in the March quarter, down from 14.4% in the previous quarter and 13.2% in the year-ago quarter. While we believe the market is concerned that the company’s operating margin guidance of 12.9% for the nutrition business in fiscal 2025 is somewhat aggressive, we are confident that Meiji’s strong branding will allow the company to improve profitability. We trim our fair value estimate for Meiji to JPY 4,200 from JPY 4,400 as we refresh our operating margin outlook for the food segment, but we continue to believe that Meiji’s shares are undervalued as the market underestimates its pricing power.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid Japanese yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of more than 11% CAGR in operating profits for the three-year plan ending March 2027.
Stock Analyst Note

Meiji’s December-quarter sales grew by 6.6%, but operating income declined by 12.6%, mainly due to a one-off valuation loss in the pharmaceutical segment. Nonetheless, we believe Meiji should still be able to achieve its full-year guidance for revenue of JPY 1.16 trillion and operating profit of JPY 86 billion, with better profitability in the food segment due to price increases. We broadly maintain our fiscal 2024 (ending March 2025) forecasts and fair value estimate of JPY 4,400 per share. We believe Meiji’s shares are undervalued currently, as we remain confident in Meiji’s strong intangible assets, such as brands and long-term relationships with retailers and suppliers, which can help underpin its pricing power and overcome cost and socioeconomic headwinds in the future.
Stock Analyst Note

Narrow-moat Meiji’s first-quarter profits were lifted by solid pharmaceutical growth. On the other hand, increased marketing investment and widened losses in China depressed profits of the moaty food business. Volume contraction of the lucrative probiotic business remains a key concern while demand for vaccines, including the ones for influenza and a new one for covid-19, will be the key swing factor to the profit outlook for the rest of the year. Given limited visibility to the vaccine demand, we have maintained our forecasts and fair value estimate of JPY 4,400. We continue to view shares trading at a 17% discount to our intrinsic value as undervalued. Yet, despite Meiji’s ability to generate cash flow, we think the absence of top-line growth remains a key negative weighing on its share price. Our operating profit projection for fiscal 2024 ended March is a touch below management’s guidance.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will serve as a key driving force behind Meiji’s midterm growth. In the near term, restoring margins squeezed by rapid Japanese yen depreciation and cost inflation and minimizing China losses is a priority. Meanwhile, restructuring efforts to enhance pharmaceutical profitability have borne fruit. Pharma profit growth, lifted by new vaccines and overseas expansion, will hold equal importance as food to the fairly challenging growth target of more than 11% CAGR in operating profits for the three-year plan ending March 2027.
Company Report

Margin expansion through growth in value-added health foods and an enlarged overseas sales scale will continue to serve as a key driving force behind Meiji’s midterm growth. Meiji’s efforts to raise profitability through growth in premium functional foods, rationalization of its product portfolio, and cost-cutting initiatives have borne fruit, with margins expanding since bottoming in fiscal 2011. Yet the pace of margin expansion has been slowing.
Stock Analyst Note

Narrow-moat Meiji’s profit guidance for fiscal 2026 (ending March 2027), indicating a 38% increase in operating profits over the three-year period, looks challenging without a sizable correction in input costs or a clear revival plan for the domestic consumer product business. We deem recovery of the probiotic yogurt and plain yogurt sales volume crucial to restoring margins and profitability. We have marginally lifted our fair value estimate to JPY 4,400 per share from JPY 4,350 to reflect the increased time value of money. Despite a handsome 31% upside to our intrinsic value, investors’ appetite for Meiji may not rebound until it delivers meaningful top-line growth, which requires new hit products to bolster domestic sales or rapid distribution expansion overseas.

Sponsor Center